Tryp Therapeutics Launches Clinical Trials to Investigate Psilocybin for Over-Eating Disorders Post published:February 16, 2021 Post category:Analysis/Editorial
Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program Post published:February 16, 2021 Post category:Press Release
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor Post published:February 11, 2021 Post category:Press Release
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller Post published:February 8, 2021 Post category:Press Release
Tryp Therapeutics Announces Strategic Investment of $2,000,000 Post published:February 5, 2021 Post category:Press Release
Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman Post published:February 3, 2021 Post category:Press Release
Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board Post published:February 2, 2021 Post category:Press Release
Tryp Therapeutics Invited to Present at “Investing in Psychedelics” Conference Post published:January 19, 2021 Post category:Press Release
James Kuo, CEO and Co-founder of Tryp Therapeutics Post published:January 15, 2021 Post category:Interview
Tryp Therapeutics Strengthens Board of Directors With Appointment of Gregory M. McKee Post published:January 14, 2021 Post category:Press Release